Genmab A/S announced DARZALEX sales results for the full year 2023. For the year, the company reported worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 9,744 million in 2023. Net trade sales were USD 5,277 million in the U.S. and USD 4,467 million in the rest of the world.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,824 DKK | +0.82% |
|
+3.15% | -15.59% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.59% | 16.79B | |
+21.55% | 127B | |
+24.85% | 117B | |
+26.35% | 27.67B | |
-18.83% | 20.33B | |
-17.91% | 15.63B | |
+13.35% | 14.84B | |
-47.70% | 14.65B | |
+56.85% | 14.43B | |
+149.50% | 12.49B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab A/S Announces DARZALEX Sales Results for the Full Year 2023